ECEESPE2025 ePoster Presentations Multisystem Endocrine Disorders (51 abstracts)
Unraveling biological determinants of advanced fibrosis risk in type 2 diabetes patients with MASLD
Yesmine Elloumi 1 , Mouna Elleuch 1 , Yasmine Abdelkafi 1 , Nada Hassairi 1 , Kouloud Boujelben 1 , Hadjkacem Faten 1 , Nadia Charfi 1 , Mouna Mnif 1 , Dhoha Ben Salah 1 & Nabila Rekik Majdoub 1
1Hedi Chaker University Hospital, Endocrinology Department, Sfax, Tunisia
JOINT468
Introduction: Metabolic-Associated Steatotic Liver Disease (MASLD) is increasingly prevalent among patients with Type 2 Diabetes Mellitus (T2DM), often leading to advanced fibrosis. Identifying biological factors that influence fibrosis risk in this population is crucial for improving patient outcomes. This study aims to explore the key biological determinants associated with advanced fibrosis in T2DM patients with MASLD.
Methods: We realized a comparative and analytical study including T2DM patients with confirmed MASLD, followed at the Endocrinology-Diabetology Department of Hedi Chaker University Hospital in Sfax, Tunisia. We used the fibrosis-4 index (FIB-4) and the NAFLD fibrosis score (NFS) to evaluate the risk of advanced fibrosis among patients. High risk of advanced fibrosis was indicated by a FIB-4 score exceeding 2.67 and an NFS score exceeding 0.675. The patients were categorized into two groups: a high-risk group for advanced fibrosis and an intermediate and low-risk group.
Results: 101 T2DM patients with MASLD were included. Liver enzymes and platelet count were excluded from the analysis as they are integral components of the NFS and FIB-4 scores. When groups were formed based on the NFS score, the prothrombin level was significantly lower in the high-risk advanced fibrosis group compared to the other group (78.0 [50.0-98.0] vs. 99.0 [94.0-100.0], respectively; P = 0.008). Comparison of groups based on the FIB-4 score did not confirm this significant difference in prothrombin level but revealed other significant associations: elevated alkaline phosphatase levels were linked to a higher risk of advanced fibrosis (P = 0.033), and albumin levels were lower in the high-risk group (P = 0.041). Other biological parameters, including total bilirubin, conjugated bilirubin, gamma-glutamyl transferase, thyroid-stimulating hormone, and uric acid, were not associated with advanced fibrosis risk regardless of the scoring method used.
Conclusion: Biological parameters such are crucial for assessing fibrosis risk in T2DM patients with MASLD, highlighting the need for comprehensive biomarker evaluation in this population.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more